ANAVEX LIFE SCIENCES CORP. - COMMON STOCK

NetDania - New 12 months High: ANAVEX LIFE SCIENCES CORP. - COMMON STOCK

26 12 2024 11:00:28 提供 NetDania Notify

NetDania - New 12 months High: ANAVEX LIFE SCIENCES CORP. - COMMON STOCK

24 12 2024 08:45:04 提供 NetDania Notify

NetDania - New 12 months High: ANAVEX LIFE SCIENCES CORP. - COMMON STOCK

23 12 2024 08:57:16 提供 NetDania Notify

Anavex Life Sciences Reports Fiscal 2024 Fourth Quarter Financial Results and Provides Business Update

23 12 2024 06:30:00 提供 Nasdaq GlobeNewswire

Blarcamesine Receives EMA Filing Acceptance for Treatment of Alzheimer’s Disease

23 12 2024 06:00:00 提供 Nasdaq GlobeNewswire

Anavex Life Sciences to Announce Fiscal 2024 Fourth Quarter Financial Results on Monday, December 23, 2024

16 12 2024 06:30:00 提供 Nasdaq GlobeNewswire

Anavex Life Sciences to Report New Long-Term Oral Blarcamesine Phase IIb/III Alzheimer’s Disease Data at J.P. Morgan 2025 Healthcare Conference

09 12 2024 06:30:00 提供 Nasdaq GlobeNewswire

Anavex Life Sciences to Present at the 7th Annual Evercore ISI HealthCONx Conference 2024

02 12 2024 06:30:00 提供 Nasdaq GlobeNewswire

Anavex Life Sciences Announces Submission of Blarcamesine MAA for Treatment of Alzheimer’s Disease to EMA

26 11 2024 06:30:00 提供 Nasdaq GlobeNewswire

Anavex Life Sciences Announces Acceptance of Peer-Reviewed Manuscript of Oral Blarcamesine Phase IIb/III Data in a Reference Alzheimer’s Disease Journal

25 11 2024 06:30:00 提供 Nasdaq GlobeNewswire

Anavex’s Blarcamesine Achieves Pre-specified Efficacy in Phase IIb/III Alzheimer’s Trial: Data Presented at CTAD Conference 2024

31 10 2024 03:00:00 提供 Nasdaq GlobeNewswire

Anavex Life Sciences Announces Encouraging Preliminary Biomarker Results from Ongoing Phase 2 Study of ANAVEX®3-71 for the Treatment of Schizophrenia

17 10 2024 06:30:00 提供 Nasdaq GlobeNewswire

Anavex Life Sciences to Present at the H.C. Wainwright 26th Annual Global Investment Conference 2024

03 9 2024 06:30:00 提供 Nasdaq GlobeNewswire

Anavex Life Sciences Reports Fiscal 2024 Third Quarter Financial Results and Provides Business Update

06 8 2024 06:30:00 提供 Nasdaq GlobeNewswire

Anavex Life Sciences to Announce Fiscal 2024 Third Quarter Financial Results on Tuesday, August 6, 2024

01 8 2024 06:30:00 提供 Nasdaq GlobeNewswire

Anavex Life Sciences Announces Translational Biomarker Data for ANAVEX®2-73 (blarcamesine) in Fragile X Syndrome (Major Cause of Autism) at the 19th NFXF International Fragile X Conference

30 7 2024 06:30:00 提供 Nasdaq GlobeNewswire

Results from Anavex Life Sciences Landmark Phase IIb/III Trial of Blarcamesine Presented at Alzheimer's Association Conference

28 7 2024 16:00:00 提供 Nasdaq GlobeNewswire

Anavex Life Sciences to Present at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference

20 6 2024 06:30:00 提供 Nasdaq GlobeNewswire

Anavex Life Sciences Announces Expansion of Leadership Team

22 5 2024 06:30:00 提供 Nasdaq GlobeNewswire

Anavex Life Sciences to Present at the H.C. Wainwright 2nd BioConnect Investor Conference at NASDAQ

14 5 2024 06:30:00 提供 Nasdaq GlobeNewswire